Acetildenafil

Acetildenafil

Clinical data
MedlinePlus	a699015
Routes of administration	By mouth
ATC code	None
Legal status
Legal status	US: OTC
Identifiers
IUPAC name 5-[2-Ethoxy-5-[2-(4-ethyl-piperazin-1-yl)-acetyl]-phenyl]-1-methyl-3-propyl-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one
CAS Number	831217-01-7 N
PubChem CID	29918992
ChemSpider	23976138 Y
UNII	TP0E2BW57H
Chemical and physical data
Formula	C25H34N6O3
Molar mass	466.574 g/mol
3D model (Jmol)	Interactive image
SMILES CCCc1nn(C)c3c1nc([nH]c3=O)-c2cc(ccc2OCC)C(=O)CN4CCN(CC)CC4
InChI InChI=1S/C25H34N6O3/c1-5-8-19-22-23(29(4)28-19)25(33)27-24(26-22)18-15-17(9-10-21(18)34-7-3)20(32)16-31-13-11-30(6-2)12-14-31/h9-10,15H,5-8,11-14,16H2,1-4H3,(H,26,27,33) Y Key:RRBRQNALHKQCAI-UHFFFAOYSA-N Y
NY (what is this?)

Acetildenafil (hongdenafil) is a synthetic drug which acts as a phosphodiesterase inhibitor. It is an analog of sildenafil (Viagra) which has been detected in numerous different brands of supposedly "herbal" aphrodisiac products sold to boost libido and alleviate erectile dysfunction.

A range of designer analogs of licensed PDE₅ inhibitors such as sildenafil and vardenafil have been detected in recent years in over-the-counter herbal aphrodisiac products, in an apparent attempt to circumvent both the legal restrictions on sale of erectile dysfunction drugs, which are prescription-only medicines in most Western countries, and the patent protection which allows sale of these drugs by competitors only with permission from the patent holders (typically, under a license from the inventors) and to introduce efficacy into otherwise ineffective herbal products. These compounds have been demonstrated to display PDE₅ inhibitory activity in vitro and presumably have similar effects when consumed, but have undergone no formal testing in either humans or animals, and as such may represent significant health risks to consumers of these products due to their unknown safety profile. Some attempts have been made to ban these drugs as unlicensed medicines, but progress has been slow so far, as even in those jurisdictions which have laws targeting designer drugs, the laws are drafted to ban analogs of illegal drugs of abuse, rather than analogs of prescription medicines. However, at least one court case has resulted in a product being taken off the market.